Gastroprotection among new chronic users of non-steroidal anti-inflammatory drugs: a study of utilization and adherence in the Netherlands
| Autor: | Ron M. C. Herings, Myrthe P. P. van Herk-Sukel, Bart J F van den Bemt, Ernst J. Kuipers, Michiel W. van der Linden, Sabine Gaugris |
|---|---|
| Přispěvatelé: | Rehabilitation Medicine, Gastroenterology & Hepatology, Gastroenterology and hepatology, Epidemiology and Data Science |
| Rok vydání: | 2009 |
| Předmět: |
Drug Utilization
Drug medicine.medical_specialty Index date media_common.quotation_subject Pharmacology Cohort Studies Drug Utilization Review SDG 3 - Good Health and Well-being Diabetes mellitus Internal medicine medicine Humans Cyclooxygenase Inhibitors Stomach Ulcer Risk factor Netherlands Retrospective Studies media_common business.industry Anti-Inflammatory Agents Non-Steroidal General Medicine medicine.disease Non steroidal anti inflammatory Rheumatoid arthritis Heart failure Patient Compliance business |
| Zdroj: | Current Medical Research & Opinion, 25(1), 195-204. Taylor & Francis Ltd Van Der Linden, M W, Gaugris, S, Kuipers, E J, Van Den Bemt, B J F, Van Herk-Sukel, M P P & Herings, R M C 2009, ' Gastroprotection among new chronic users of non-steroidal anti-inflammatory drugs : A study of utilization and adherence in the Netherlands ', Current Medical Research and Opinion, vol. 25, no. 1, pp. 195-204 . https://doi.org/10.1185/03007990802632915 Current Medical Research and Opinion, 25(1), 195-204. Taylor and Francis Ltd. |
| ISSN: | 0300-7995 |
| DOI: | 10.1185/03007990802632915 |
| Popis: | Objective: To describe the use of gastroprotection (GP) among new chronic users of NSAIDs in the Netherlands by gastrointestinal (GI) risk factor (RF) score. Methods: Data for this retrospective follow-up study were extracted from the PHARMO database. We selected new chronic users of COX-2 inhibitors (coxibs) or traditional NSAIDs (tNSAIDs) between 1st January 2000 and 31st December 2004. GP strategies were defined as: use of proton pump inhibitors (PPI), coxibs or both. GI RF score at index date was based on: history of GI drug use, high dose of NSAIDs, age > 60 years, use of corticosteroids/anticoagulants/SSRIs, rheumatoid arthritis, heart failure or diabetes, with each condition accounting for one factor. Switching was assessed among those with >= 1 GI RF during the first year of follow-up. Results: Among 58 770 new chronic NSAID users at index date, 80% used tNSAIDs alone, 8% used tNSAID+PPI, 10% used a coxib alone and 2% used coxib+PPI. Mean (SD) number of GI RF among these groups was 1.6 (2.1), 3.1 (1.3), 1.5 (1.5) and 2.8 (1.3), respectively. Among 48 390 patients (82.3%) with a GI RF score of >= 1, 20.9% used a GP strategy, this increased with number of GI RFs. Within the first year, 5.3% (n = 2067) and 4.8%(n = 1 843) of tNSAID users with >= 1 GI RF switched to tNSAID+PPI and coxib alone, respectively. Conclusions: Gastroprotection in users of tNSAIDs was inadequate. Over 80% of NSAID users with >= 1 GI RF did not receive any gastroprotection, and even when prescribed, a PPI is used only half the time. More research should show if gastroprotection was used for prevention. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|